Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Work In Process: 2014-2025

Historic Work In Process for Ocular Therapeutix (OCUL) over the last 6 years, with Sep 2025 value amounting to $1.4 million.

  • Ocular Therapeutix's Work In Process fell 2.93% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 2.93%. This contributed to the annual value of $1.5 million for FY2024, which is 47.13% up from last year.
  • Per Ocular Therapeutix's latest filing, its Work In Process stood at $1.4 million for Q3 2025, which was down 21.72% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Work In Process peaked at $1.8 million during Q1 2025, and registered a low of $402,000 during Q1 2021.
  • Over the past 3 years, Ocular Therapeutix's median Work In Process value was $1.1 million (recorded in 2024), while the average stood at $1.2 million.
  • Per our database at Business Quant, Ocular Therapeutix's Work In Process soared by 650.67% in 2021 and then decreased by 2.93% in 2025.
  • Ocular Therapeutix's Work In Process (Quarterly) stood at $605,000 in 2021, then soared by 48.60% to $899,000 in 2022, then climbed by 12.57% to $1.0 million in 2023, then surged by 47.13% to $1.5 million in 2024, then declined by 2.93% to $1.4 million in 2025.
  • Its Work In Process stands at $1.4 million for Q3 2025, versus $1.7 million for Q2 2025 and $1.8 million for Q1 2025.